Patients with severe eosinophilic asthma who received benralizumab in a real-world setting had substantially improved clinical outcomes, irrespective of prior biologic use and key clinical characteristics, including atopic status and exhaled nitric oxide fraction.
Read the article | Submit to the European Respiratory Journal
No comments:
Post a Comment